Deutsche Bank
RXRX icon

Deutsche Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Deutsche Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
542,270
+165,403
+44% +$551K ﹤0.01% 1910
2026
Q1 		$1.16M Buy
376,867
+79,363
+27% +$307K ﹤0.01% 2098
2025
Q4 		$1.22M Buy
297,504
+27,945
+10% +$138K ﹤0.01% 2092
2025
Q3 		$1.32M Buy
269,559
+29,872
+12% +$157K ﹤0.01% 2005
2025
Q2 		$1.21M Buy
239,687
+33,317
+16% +$164K ﹤0.01% 1977
2025
Q1 		$1.09M Sell
206,370
-11,353
-5% -$82.8K ﹤0.01% 2104
2024
Q4 		$1.47M Buy
217,723
+75,994
+54% +$511K ﹤0.01% 2026
2024
Q3 		$934K Buy
141,729
+31,852
+29% +$228K ﹤0.01% 2148
2024
Q2 		$824K Buy
109,877
+28,795
+36% +$251K ﹤0.01% 2093
2024
Q1 		$808K Buy
81,082
+2,735
+3% +$30.5K ﹤0.01% 2114
2023
Q4 		$773K Buy
78,347
+18,659
+31% +$133K ﹤0.01% 2161
2023
Q3 		$457K Buy
59,688
+7,973
+15% +$79.5K ﹤0.01% 2225
2023
Q2 		$386K Sell
51,715
-36,945
-42% -$259K ﹤0.01% 2500
2023
Q1 		$591K Buy
88,660
+17,687
+25% +$140K ﹤0.01% 2397
2022
Q4 		$547K Buy
70,973
+12,903
+22% +$127K ﹤0.01% 2400
2022
Q3 		$618K Sell
58,070
-6,248
-10% -$63.3K ﹤0.01% 2262
2022
Q2 		$523K Sell
64,318
-1,481
-2% -$9.91K ﹤0.01% 2566
2022
Q1 		$471K Sell
65,799
-7,002
-10% -$74.4K ﹤0.01% 2789
2021
Q4 		$1.25M Buy
72,801
+56,039
+334% +$1.05M ﹤0.01% 2304
2021
Q3 		$385K Buy
16,762
+3,640
+28% +$103K ﹤0.01% 3202
2021
Q2 		$479K Buy
+13,122
New +$388K ﹤0.01% 3252

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank's RXRX Position: Q2 2026 in Review

Deutsche Bank increased its Recursion Pharmaceuticals (RXRX) stake by 44% in Q2 2026, buying an estimated $551K and bringing the position to 542,270 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

Deutsche Bank first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Deutsche Bank held 542,270 shares of Recursion Pharmaceuticals worth $1.99M as of Q2 2026.
  • Deutsche Bank bought 165,403 Recursion Pharmaceuticals shares in Q2 2026, an estimated $551K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1910 holding.
  • Deutsche Bank first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.